Author

Bo Young Cho

Observed name: BOYOUNG CHO

Institution: Daewoong Pharmaceutical (South Korea)

Observed institution: Daewoong Pharmaceutical (South Korea)

ORCID: 0000-0002-8422-9966

Observed ORCID: 0000-0002-8422-9966

OpenAlex ID: A5064648726

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial

2023 · Soo Heon Kwak, Kyung Ah Han, et al. · Diabetes Obesity and Metabolism · 30

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

2024 · Young Sang Lyu, Sangmo Hong, et al. · Cardiovascular Diabetology · 9

940-P: Efficacy and Safety of Enavogliflozin vs. Dapagliflozin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Based on Renal Function—A Pooled Analysis of Two Randomized Controlled Trials

2024 · YOUNG SANG LYU, SANG MO HONG, et al. · Diabetes

Author response for "Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase III trial"

2023 · Soo Heon Kwak, Kyung Ah Han, et al. · Publons reviews and discussion

Works count: 4

Citation count: 39

H-index: 2

I10-index: 1